Summit Therapeutics Inc. Total Liabilities
Summit Therapeutics Inc. (SMMT) had Total Liabilities of $122.20 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-23
- 2026-06-30: Liabilities $122.20M.
- 2026-03-31: Liabilities $101.92M.
- 2025-12-31: Liabilities $92.32M.
- 2025-09-30: Liabilities $69.47M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $122.20M 10-Q · filed 2026-07-23 | |
| 2026-03-31 | $101.92M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $92.32M 10-Q · filed 2026-07-23 | |
| 2025-09-30 | $69.47M 10-Q · filed 2025-10-20 | |
| 2025-06-30 | $64.60M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $39.49M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $46.81M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $64.93M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $146.78M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $132.57M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $125.26M 10-K · filed 2025-02-24 | |
| 2023-09-30 | $119.10M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $117.77M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $121.42M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $537.51M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $22.08M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $44.40M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $52.06M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $30.09M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $26.38M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $26.09M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $76.39M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $23.05M 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $20.00M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $19.00M 8-K · filed 2020-09-29 | |
| 2019-12-31 | $17.39M 10-K · filed 2021-03-31 | $19.44M 8-K · filed 2020-09-29 |
| 2019-01-31 | $23.75M 8-K · filed 2020-09-29 | |
| 2018-01-31 | $82.67M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |